Neurocrine Book Value Per Share from 2010 to 2025

NBIX Stock

USD 115.02 0.00 0.00%

Neurocrine Biosciences Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Neurocrine Biosciences according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

25.7938247

Current Value

27.08

Quarterly Volatility

8.97528977

Credit Downgrade

Yuan Drop

Covid

Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 7.4 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.

Check out the analysis of Neurocrine Biosciences Correlation against competitors.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Neurocrine Biosciences over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Neurocrine Biosciences' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 26.05 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Neurocrine Book Value Per Share Regression Statistics

	Arithmetic Mean	9.87
	Geometric Mean	6.42
	Coefficient Of Variation	90.95
	Mean Deviation	7.62
	Median	5.04
	Standard Deviation	8.98
	Sample Variance	80.56
	Range	25.9911
	R-Value	0.90
	Mean Square Error	16.49
	R-Squared	0.81
	Slope	1.70
	Total Sum of Squares	1,208

Neurocrine Book Value Per Share History

	2025	27.08
	2024	25.79
	2023	22.85
	2022	17.83
	2021	14.52
	2020	12.1
	2019	6.95

Other Fundumenentals of Neurocrine Biosciences

Tangible Book Value Per Share

Neurocrine Biosciences Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.47	0.62	0.99	0.98	0.97	0.99	0.58	0.87	0.94	0.77	0.58	0.89	0.83	0.96	0.83	0.54	0.98	-0.8	0.74	-0.73	0.83	0.92
Total Stockholder Equity	0.99		0.42	0.67	0.98	0.99	0.93	0.97	0.54	0.86	0.92	0.7	0.55	0.86	0.86	0.98	0.8	0.5	0.97	-0.84	0.73	-0.72	0.86	0.93
Net Debt	0.47	0.42		0.13	0.5	0.47	0.56	0.49	0.76	0.22	0.48	0.6	0.25	0.48	0.41	0.32	0.44	0.34	0.55	0.05	0.23	-0.24	0.14	0.28
Retained Earnings	0.62	0.67	0.13		0.67	0.7	0.48	0.54	0.18	0.57	0.45	0.13	-0.14	0.46	0.75	0.64	0.24	0.26	0.6	-0.74	0.52	-0.38	0.67	0.71
Accounts Payable	0.99	0.98	0.5	0.67		0.99	0.95	0.97	0.65	0.85	0.92	0.72	0.52	0.88	0.84	0.93	0.79	0.53	0.97	-0.76	0.75	-0.66	0.8	0.89
Net Receivables	0.98	0.99	0.47	0.7	0.99		0.92	0.97	0.59	0.84	0.92	0.67	0.51	0.85	0.9	0.96	0.77	0.49	0.95	-0.8	0.69	-0.68	0.84	0.91
Total Liab	0.97	0.93	0.56	0.48	0.95	0.92		0.97	0.66	0.84	0.94	0.89	0.61	0.92	0.72	0.89	0.86	0.61	0.96	-0.68	0.73	-0.73	0.74	0.85
Total Current Assets	0.99	0.97	0.49	0.54	0.97	0.97	0.97		0.62	0.87	0.97	0.82	0.64	0.92	0.81	0.96	0.88	0.58	0.95	-0.75	0.66	-0.76	0.82	0.88
Short Term Debt	0.58	0.54	0.76	0.18	0.65	0.59	0.66	0.62		0.4	0.68	0.65	0.38	0.6	0.42	0.41	0.55	0.43	0.58	-0.08	0.33	-0.17	0.18	0.42
Intangible Assets	0.87	0.86	0.22	0.57	0.85	0.84	0.84	0.87	0.4		0.81	0.68	0.52	0.91	0.66	0.9	0.75	0.66	0.8	-0.79	0.62	-0.79	0.8	0.83
Short Term Investments	0.94	0.92	0.48	0.45	0.92	0.92	0.94	0.97	0.68	0.81		0.82	0.66	0.89	0.75	0.89	0.87	0.6	0.88	-0.66	0.61	-0.75	0.76	0.81
Long Term Debt	0.77	0.7	0.6	0.13	0.72	0.67	0.89	0.82	0.65	0.68	0.82		0.65	0.85	0.43	0.68	0.84	0.64	0.76	-0.4	0.49	-0.69	0.52	0.6
Common Stock	0.58	0.55	0.25	-0.14	0.52	0.51	0.61	0.64	0.38	0.52	0.66	0.65		0.61	0.3	0.59	0.88	0.46	0.55	-0.33	0.48	-0.57	0.54	0.51
Property Plant Equipment	0.89	0.86	0.48	0.46	0.88	0.85	0.92	0.92	0.6	0.91	0.89	0.85	0.61		0.6	0.88	0.88	0.71	0.85	-0.62	0.61	-0.8	0.72	0.77
Current Deferred Revenue	0.83	0.86	0.41	0.75	0.84	0.9	0.72	0.81	0.42	0.66	0.75	0.43	0.3	0.6		0.83	0.55	0.29	0.8	-0.75	0.48	-0.55	0.81	0.79
Net Tangible Assets	0.96	0.98	0.32	0.64	0.93	0.96	0.89	0.96	0.41	0.9	0.89	0.68	0.59	0.88	0.83		0.82	0.5	0.92	-0.88	0.66	-0.79	0.9	0.92
Capital Surpluse	0.83	0.8	0.44	0.24	0.79	0.77	0.86	0.88	0.55	0.75	0.87	0.84	0.88	0.88	0.55	0.82		0.66	0.8	-0.54	0.63	-0.74	0.74	0.74
Deferred Long Term Liab	0.54	0.5	0.34	0.26	0.53	0.49	0.61	0.58	0.43	0.66	0.6	0.64	0.46	0.71	0.29	0.5	0.66		0.49	-0.28	0.47	-0.61	0.51	0.49
Long Term Investments	0.98	0.97	0.55	0.6	0.97	0.95	0.96	0.95	0.58	0.8	0.88	0.76	0.55	0.85	0.8	0.92	0.8	0.49		-0.74	0.79	-0.68	0.78	0.87
Long Term Debt Total	-0.8	-0.84	0.05	-0.74	-0.76	-0.8	-0.68	-0.75	-0.08	-0.79	-0.66	-0.4	-0.33	-0.62	-0.75	-0.88	-0.54	-0.28	-0.74		-0.6	0.63	-0.86	-0.89
Net Invested Capital	0.74	0.73	0.23	0.52	0.75	0.69	0.73	0.66	0.33	0.62	0.61	0.49	0.48	0.61	0.48	0.66	0.63	0.47	0.79	-0.6		-0.53	0.68	0.75
Short Long Term Debt	-0.73	-0.72	-0.24	-0.38	-0.66	-0.68	-0.73	-0.76	-0.17	-0.79	-0.75	-0.69	-0.57	-0.8	-0.55	-0.79	-0.74	-0.61	-0.68	0.63	-0.53		-0.82	-0.68
Net Working Capital	0.83	0.86	0.14	0.67	0.8	0.84	0.74	0.82	0.18	0.8	0.76	0.52	0.54	0.72	0.81	0.9	0.74	0.51	0.78	-0.86	0.68	-0.82		0.89
Capital Stock	0.92	0.93	0.28	0.71	0.89	0.91	0.85	0.88	0.42	0.83	0.81	0.6	0.51	0.77	0.79	0.92	0.74	0.49	0.87	-0.89	0.75	-0.68	0.89

Click cells to compare fundamentals

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	25.79	27.08
Tangible Book Value Per Share	25.43	26.70

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC